| Drug Name |
Fosamprenavir calcium |
| Drug ID |
BADD_D00961 |
| Description |
Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. |
| Indications and Usage |
Indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission. The use of fosamprenavir is pending revision due to a potential association between the drug and myocardial infarction and dyslipidemia in HIV infected adults. |
| Marketing Status |
approved |
| ATC Code |
J05AE07 |
| DrugBank ID |
DB01319
|
| KEGG ID |
D03835
|
| MeSH ID |
C426859
|
| PubChem ID |
131535
|
| TTD Drug ID |
D0F5MT
|
| NDC Product Code |
49702-208; 65015-806; 49702-207; 63379-087; 63304-583; 0378-3520 |
| UNII |
ID1GU2627N
|
| Synonyms |
fosamprenavir | fos-amprenavir | (3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)carbamic acid C-(tetrahydro-3-furanyl) ester | VX-175 | VX 175 | GW-433908 | GW 908 | GW433908 | GW 433908 | GW-908 | fosamprenavir sodium | GW 433908A | GW-433908A | fosamprenavir calcium | Telzir | GW 433908G | GW-433908G | GW433908G | Lexiva |
